Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Safety and Clinical Activity in Patients With Advanced Chondrosarcoma

2020154 citationsJournal Articlebronze Open Access

Authors

William D. Tap · Memorial Sloan Kettering Cancer Center

Víctor M. Villalobos · University of Colorado Anschutz Medical Campus

Gregory M. Coté · Massachusetts General Hospital

Howard A. Burris · Sarah Cannon

Filip Jankú · The University of Texas MD Anderson Cancer Center

Olivier Mir · Institut Gustave Roussy

M. Beeram

Abstract

In patients with chondrosarcoma, ivosidenib showed minimal toxicity, substantial 2-HG reduction, and durable disease control. Future studies of ivosidenib monotherapy or rational combination approaches should be considered in patients with advanced mutant <i>IDH1</i> chondrosarcoma.

Topics & Keywords

Sarcoma Diagnosis and Treatment Multiple Myeloma Research and Treatments Bone Tumor Diagnosis and Treatments

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Clinical Oncology

Volume 38, Issue 15, pp. 1693-1701

DOI: 10.1200/jco.19.02492

Field-Weighted Citation Impact: 10.51